Leucine/metformin/sildenafil - NuSirt Biopharma

Drug Profile

Leucine/metformin/sildenafil - NuSirt Biopharma

Alternative Names: Leu-Met-Sil; Leucine/sildenafil/metformin; Metformin/leucine/sildenafil; Metformin/sildenafil/leucine; NS-0200; Sildenafil/leucine/metformin; Sildenafil/metformin/leucine

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuSirt Biopharma
  • Class Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; SIRT1 protein stimulants; Sirtuin modulators; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Obesity
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Jan 2018 Phase-II clinical trials in Obesity in USA (PO) (NCT03364335)
  • 14 Dec 2017 NuSirt Biopharma plans a phase II trial for Obesity in January 2018 (PO) (NCT03364335)
  • 20 Sep 2016 NuSirt Biopharma completes enrolment in its phase II trial for Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top